Previous 10 | Next 10 |
Greenland Technologies (GTEC) -13% after prices $7.0M underwritten public offering of ordinary shares.Alnylam Pharmaceuticals (ALNY) -10%.Trevena (TRVN) -10% on addition to Russell 2000, Russell 3000, and Russell Microcap Indexes.Atossa Therapeutics (ATOS) -10%.Exelixis (EXEL)&...
Alnylam Pharmaceuticals (ALNY) announces that the FDA has accepted its New Drug Application ((NDA)) for vutrisiran, an investigational RNAi therapeutic for the treatment of the polyneuropathy of hereditary transthyretin-mediated (hATTR) amyloidosis in adults.The FDA has set PDUFA target actio...
– PDUFA Date Set for April 14, 2022 – Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that the U.S. Food and Drug Administration (FDA) has accepted the Company’s New Drug Application (NDA) for vutr...
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it plans to host its 8 th annual series of “RNAi Roundtable” webinars over the coming weeks. The series will offer a range of presentations from Alnylam scient...
− Phase 3b Open-Label Study Showed Treatment with Patisiran Achieved Rapid and Sustained Reduction in Serum TTR Levels in hATTR Amyloidosis Patients with Polyneuropathy Progression Following Orthotopic Liver Transplant – − Additional Results from Pre-speci...
− APOLLO-B is the Industry’s Furthest Progressed Randomized, Double-Blind, Placebo-Controlled Pivotal Study of an Investigational TTR Silencer in Hereditary and Wild-type ATTR Amyloidosis with Cardiomyopathy − − Topline Results Expected in Mid-2022 ...
Alnylam has posted improving sales figures for Onpattro and positive pivotal data from the HELIOS-A study, but the hATTR program needs positive outcomes from ongoing cardiomyopathy studies in 2022/23. This year may be light on thesis-changing data, as most of the bigger data outcomes ...
− Initiates Clinical Study of Biannual Dosing Regimen of Investigational Vutrisiran in hATTR Patients with Polyneuropathy, with Data Expected in 2022 Potentially Supporting sNDA Submission – − Introduces New ATTR Program Aimed at Achieving Annual Dosing Re...
Dicerna approached doubling from its 52-week low, then drifted lower recently. Cash was raised recently from a royalty deal; has a runway to 2024. The platform and pipeline remain poised for long-term value. For further details see: Dicerna A Buy On Long-Term Potential ...
Alnylam Pharmaceuticals (ALNY) announces positive early results from the 12-month analysis of ILLUMINATE-A Phase 3 study of OXLUMO (lumasiran) for the treatment of primary hyperoxaluria type 1 (PH1). Among 24 patients in ILLUMINATE-A who had been treated with lumasiran for 12 months, 46% (11/...
News, Short Squeeze, Breakout and More Instantly...
Alnylam Pharmaceuticals Inc. Company Name:
ALNY Stock Symbol:
NASDAQ Market:
Alnylam Pharmaceuticals Inc. Website:
Alnylam Pharmaceuticals, Inc. (Nasdaq: ALNY), the leading RNAi therapeutics company, announced today that it will report financial results for the second quarter ending June 30, 2024 on Thursday, August 1, 2024, before the U.S. financial markets open. Management will provide an update on th...
2024-06-29 16:24:00 ET Stock Traders Daily has produced this trading report using a proprietary method. This methodology seeks to optimize the entry and exit levels to maximize results and limit risk, and it is also applied to Index options, ETFs, and futures for our subscribers. This...